239 related articles for article (PubMed ID: 29026042)
1. Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV.
Wender PA; Hardman CT; Ho S; Jeffreys MS; Maclaren JK; Quiroz RV; Ryckbosch SM; Shimizu AJ; Sloane JL; Stevens MC
Science; 2017 Oct; 358(6360):218-223. PubMed ID: 29026042
[TBL] [Abstract][Full Text] [Related]
2. In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.
Marsden MD; Loy BA; Wu X; Ramirez CM; Schrier AJ; Murray D; Shimizu A; Ryckbosch SM; Near KE; Chun TW; Wender PA; Zack JA
PLoS Pathog; 2017 Sep; 13(9):e1006575. PubMed ID: 28934369
[TBL] [Abstract][Full Text] [Related]
3. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro.
DeChristopher BA; Loy BA; Marsden MD; Schrier AJ; Zack JA; Wender PA
Nat Chem; 2012 Sep; 4(9):705-10. PubMed ID: 22914190
[TBL] [Abstract][Full Text] [Related]
4. Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications.
Wu R; Chen H; Chang N; Xu Y; Jiao J; Zhang H
Chemistry; 2020 Jan; 26(6):1166-1195. PubMed ID: 31479550
[TBL] [Abstract][Full Text] [Related]
5. Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window.
Sloane JL; Benner NL; Keenan KN; Zang X; Soliman MSA; Wu X; Dimapasoc M; Chun TW; Marsden MD; Zack JA; Wender PA
Proc Natl Acad Sci U S A; 2020 May; 117(20):10688-10698. PubMed ID: 32371485
[TBL] [Abstract][Full Text] [Related]
6. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.
Pérez M; de Vinuesa AG; Sanchez-Duffhues G; Marquez N; Bellido ML; Muñoz-Fernandez MA; Moreno S; Castor TP; Calzado MA; Muñoz E
Curr HIV Res; 2010 Sep; 8(6):418-29. PubMed ID: 20636281
[TBL] [Abstract][Full Text] [Related]
7. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
[TBL] [Abstract][Full Text] [Related]
8. Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs.
Wender PA; Nakagawa Y; Near KE; Staveness D
Org Lett; 2014 Oct; 16(19):5136-9. PubMed ID: 25238583
[TBL] [Abstract][Full Text] [Related]
9. Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV.
Wender PA; Kee JM; Warrington JM
Science; 2008 May; 320(5876):649-52. PubMed ID: 18451298
[TBL] [Abstract][Full Text] [Related]
10. Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment.
Relaño-Rodríguez I; Juárez-Sánchez R; Pavicic C; Muñoz E; Muñoz-Fernández MÁ
J Nanobiotechnology; 2019 May; 17(1):69. PubMed ID: 31113488
[TBL] [Abstract][Full Text] [Related]
11. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
[TBL] [Abstract][Full Text] [Related]
12. Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold.
Wender PA; Staveness D
Org Lett; 2014 Oct; 16(19):5140-3. PubMed ID: 25238640
[TBL] [Abstract][Full Text] [Related]
13. Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4
Zerbato JM; Tachedjian G; Sluis-Cremer N
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993846
[TBL] [Abstract][Full Text] [Related]
14. Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism.
Díaz L; Martínez-Bonet M; Sánchez J; Fernández-Pineda A; Jiménez JL; Muñoz E; Moreno S; Álvarez S; Muñoz-Fernández MÁ
Sci Rep; 2015 Jul; 5():12442. PubMed ID: 26199173
[TBL] [Abstract][Full Text] [Related]
15. Natural product-derived compounds in HIV suppression, remission, and eradication strategies.
Andersen RJ; Ntie-Kang F; Tietjen I
Antiviral Res; 2018 Oct; 158():63-77. PubMed ID: 30063970
[TBL] [Abstract][Full Text] [Related]
16. Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide.
Bahr GM
J Antimicrob Chemother; 2003 Jan; 51(1):5-8. PubMed ID: 12493780
[No Abstract] [Full Text] [Related]
17. HIV/AIDS eradication.
Marsden MD; Zack JA
Bioorg Med Chem Lett; 2013 Jul; 23(14):4003-10. PubMed ID: 23735743
[TBL] [Abstract][Full Text] [Related]
18. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
Bullen CK; Laird GM; Durand CM; Siliciano JD; Siliciano RF
Nat Med; 2014 Apr; 20(4):425-9. PubMed ID: 24658076
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy.
Hardman C; Ho S; Shimizu A; Luu-Nguyen Q; Sloane JL; Soliman MSA; Marsden MD; Zack JA; Wender PA
Nat Commun; 2020 Apr; 11(1):1879. PubMed ID: 32312992
[TBL] [Abstract][Full Text] [Related]
20. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.
López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Rodríguez-Mora S; Coiras M; Alcamí J; Moreno S
Sci Rep; 2017 May; 7(1):2385. PubMed ID: 28539614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
